Biotron Limited (BIT.AX)

AUD 0.02

(-5.88%)

Market Cap (In AUD)

14.43 Million

Revenue (In AUD)

-

Net Income (In AUD)

-3.43 Million

Avg. Volume

1.14 Million

Currency
AUD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.016-0.12
PE
-
EPS
-
Beta Value
-0.642
ISIN
AU000000BIT4
CUSIP
Q1527U107
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Michelle Miller BSc., GCertAppFin, MSc., Ph.D.
Employee Count
-
Website
https://www.biotron.com.au
Ipo Date
2001-01-23
Details
Biotron Limited, a biotechnology company, engages in developing and commercializing small molecule products to treat various viral diseases in Australia. The company's lead antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of SARS-CoV-2, HIV-1, and hepatitis C virus infections. Biotron Limited was incorporated in 1999 and is headquartered in Sydney, Australia.